



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Ruth Parker, M.D.

Committees: Joint meeting of the Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee

Meeting Dates: April 24-25, 2018

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item: discussion of the supplemental new drug application (NDA) 20998 for Celebrex (celecoxib) capsules submitted by Pfizer, Inc., which includes the results from the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen Or Naproxen) trial, a cardiovascular outcomes randomized controlled trial that compared celecoxib to ibuprofen and naproxen, and determine whether the findings of the trial change FDA’s current understanding of the safety of these three NSAIDs; in order to interpret some of the PRECISION findings, the committee will also consider the clinical implications of the drug interactions between each of these three NSAIDs and aspirin in patients taking aspirin for secondary prevention of cardiovascular disease, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Stocks/Investments	Spouse’s two Healthcare Sector Mutual Funds	Between \$0 - \$100,000

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/s/_____
Signature

_____/3/29/18_____
Date